• Myeloma UK
  • Clinical Service Excellence Programme
Top menu
TwitterFacebook
Myeloma Academy
Myeloma Academy

Sign in | Register

Call us for more info on 0131 557 3332

Menu
  • Home
  • CPD & Learning
    • Myeloma Nurse Learning Programme
    • My CPD Portfolio
    • Challenging Cases
    • Close
  • Library
    • Guidelines
      • Complications
      • COVID-19 guidance
      • General haemato/oncology
      • Imaging & Analysis
      • Management & Treatment
      • Palliative Care
      • Presentation & Diagnosis
      • Related conditions
      • Close
    • Patient Support and Information
    • Medical animations
    • Close
  • Resources
    • Myeloma Drug Finder
    • Myeloma Trial Finder
    • Assessment tools
    • Myeloma Spotlight
    • Primary care education
    • Secondary care education
    • Myeloma health economic model
    • Close
  • News & Events
    • News
    • Event calendar
    • Meeting highlights
    • Close
  • CSEP
  • About Us
    • Contact Us
    • Close
MENU CLOSE back  

Management & Treatment

IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide, lenalidomide or bortezomib-containing regimens

This paper, written by an expert panel of the International Myeloma Working Group, examines the impact of novel treatments on stem cell collection in myeloma patients. It summarises the available evidence and makes recommendations to address identified issues.

August 27, 2009
Download
123
Prev page
  • Guidelines
    • Complications
    • COVID-19 guidance
    • General haemato/oncology
    • Imaging & Analysis
    • Management & Treatment
    • Palliative Care
    • Presentation & Diagnosis
    • Related conditions
  • Patient Support and Information
  • Medical animations
Myeloma Academy
Bottom menu

Registered Charity
No. SC 026116
Myeloma UK
22 Logie Mill
Beaverbank Business Park
Edinburgh
EH7 4HG